A lack of evidence is behind the NHS' decision to withhold a breakthrough prostate cancer drug from patients who have already been treated using another new generation drug, Nice said.
A spokeswoman for Nice said the committee were unable to "draw any conclusions" about what would happen if "milestone" enzalutamide was used by prostate cancer sufferers who had also taken abiraterone.
In the trial data provided by the manufacturer of enzalutamide none of the patients had received previous treatment with abiraterone, therefore the committee was not able to draw any conclusions about the effectiveness of enzalutamide after previous abiraterone treatment, and this is reflected in the recommendations.
We would welcome any additional data the manufacturer of enzalutamide can provide.
More top news
A dry and fine weekend for most, with scattered showers and heavier downpours in Scotland.
Floods are an annual occurrence in parts of India during the monsoon season, which runs from June to September.
Crew members of the IchorCoal paid tribute to two sailors who died during the 11-month circumnavigation of the globe.